(Press-News.org) Marking a milestone in its role as a leading open access (OA) book publisher, Taylor & Francis has announced Technology and Sustainable Development: The Promise and Pitfalls of Techno-Solutionism as its 1,500th OA book.
Reflecting the crucial role for open access in making relevant research available to readers outside of academia, Technology and Sustainable Development focuses on many of the practical challenges facing our governments and societies today.
The potential of technology to both solve and exacerbate pressing global issues, including gender inequality, the climate crisis, mistreatment of minorities, and the unequal distribution of power, is addressed by a range of experts in the book edited by Henrik Skaug Sætra.
The book explores the implications of new technologies, such as artificial intelligence, social media and big data, as well as considering the need for greater social and political control of such developments.
James Watson, Open Access Books Lead at Taylor & Francis, said: “Our 1,500th OA book, which has human-centered science at its heart, demonstrates why open access publishing is so important. At a time of unprecedented technological change, Technology and Sustainable Development is a vital resource not just for researchers with access to university libraries but also for policymakers, politicians and all those tackling the social, economic and environmental challenges faced by our societies”.
Taylor & Francis marks 10 years of open access book publishing in 2023. With over 1,500 fully OA titles in its portfolio, combined with thousands of individual open chapters, Taylor & Francis is one of the leading open access book publishers. Its OA books program enables authors and their funders to publish open access single- or co-authored books, edited collections and individual chapters. Upon publication, OA content is made available in digital format to read and download freely under a Creative Commons license.
Technology and Sustainable Development is available for everyone to read and download for free from Taylor & Francis eBooks. Open access funding support for the book was provided by Østfold University College.
Explore the full range of Taylor & Francis open access books and chapters.
END
Taylor & Francis marks 1,500 Open Access Books milestone with essential read on technology and sustainable development
2023-06-05
ELSE PRESS RELEASES FROM THIS DATE:
More than three in five children do not receive timely mental health services after firearm injury
2023-06-05
More than three in five children (63 percent) enrolled in Medicaid do not receive mental health services within six months after a firearm injury, according to a new study published in the journal Pediatrics.
In the United States, 11,258 youth experienced nonfatal firearm injuries in 2020. Children who survive firearm injuries are at increased risk for adverse mental health outcomes, such as newly diagnosed trauma-related disorders, substance use and disruptive disorders. In addition to these disorders, the study found that ...
Saving moths may be just as important as saving the bees
2023-06-05
Night-time pollinators such as moths need protecting as effectively as bees, as new research found they could be less resilient to the pressures of urbanisation
Moths account for a third of the pollinator visits to crops, flowers and trees in urban areas
More moths were found to be carrying pollen than previously thought, and visiting more types of plant and fruit crops than previously identified
Moth abundance has declined by 33 per cent in the last 50 years and this represents a threat to the plants and crops that rely on insects for pollination
Night-time pollinators such as moths may visit just as many ...
Deadly heart attacks more common on a Monday
2023-06-05
Serious heart attacks are more likely to happen at the start of the working week than at any other time, according to new research presented today at the British Cardiovascular Society (BCS) conference in Manchester.
Doctors at the Belfast Health and Social Care Trust and the Royal College of Surgeons in Ireland analysed data of 10,528 patients across the island of Ireland (7,112 in the Republic of Ireland, 3,416 in Northern Ireland) admitted to hospital between 2013 and 2018 with the most serious type of heart attack. This is known as an ST-segment elevation myocardial infarction (STEMI) and occurs when a major coronary artery is completely blocked.
The researchers ...
Testing for ‘zombie cells’ could boost number of hearts for transplant
2023-06-05
Testing older potential organ donors for dangerous ‘zombie’ cells could help to increase the number of hearts available for transplant, according to research part-funded by the British Heart Foundation (BHF) and presented at the British Cardiovascular Society conference in Manchester.
Currently, hearts from donors aged over 65 are not accepted for donation due to the likelihood of a poor clinical outcome. However, our hearts age at different rates and age isn’t necessarily the best indicator of heart health.
Researchers ...
Whales not to be counted on as ‘climate savers’: study
2023-06-04
Do whales increase the removal of carbon from the atmosphere?
Despite some hope that this would be the case, a new study led by Griffith University and a team of global researchers has found the amount of potential carbon capture by whales is too little to meaningfully alter the course of climate change.
Marine scientist Dr Olaf Meynecke and the team from the Griffith-led Whales and Climate Research Program including Professor Brendan Mackey and Dr Jasper De Bie, reviewed the primary ways in which baleen whales (such as humpback whales) removed atmospheric carbon ...
New drug delays progression of glioma, a deadly brain cancer
2023-06-04
Key takeaways
A targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer.
In a study of 331 people with the disease, the drug was effective in lengthening the period of time before the patients’ cancer worsened, and with no observed adverse effects.
New treatment approaches for glioma are needed because current treatments, including chemotherapy and radiation, can cause neurological deficits.
In ...
University of Sydney launches innovative research fellowship scheme to tackle global challenges
2023-06-04
An unprecedented investment by the University of Sydney, Australia will support up to 40 new continuing positions, empowering the world’s most talented emerging researchers to undertake innovative research to address some of the biggest challenges of our time.
A $100 million investment and a cornerstone of the University’s 2032 Strategy, the Sydney Horizon Fellowship scheme is the first of its kind in Australia and among the most generous university fellowships in the world.
“The Sydney ...
Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer
2023-06-04
CHICAGO – Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, an important question has remained unanswered: How long should a patient with advanced non-small cell lung cancer (NSCLC), who receives immunotherapy as part of their initial treatment, continue with treatment?
A new retrospective cohort study, published today in JAMA Oncology and presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract ...
Association of immunotherapy duration with overall survival in advanced non–small cell lung cancer – this study is being released to coincide with a poster presentation at the 2023 ASCO annual meeting
2023-06-04
About The Study: The findings of this study provide reassurance that for patients with advanced non–small cell lung cancer whose disease is still responding to immune checkpoint inhibitor therapy at two years, stopping therapy and monitoring rather than continuing immunotherapy indefinitely is a reasonable strategy with sustained clinical benefit.
Authors: Lova Sun, M.D., M.S.C.E., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2023.1891)
Editor’s ...
The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer
2023-06-03
Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study* show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.
80% of patients included in this study presented with FolRα expression levels higher than 25%. The overall response rate among these patients was 43.8% in the dose expansion cohort, with a median duration of response ...